Why you Should Care about Activities Related to Clinical Trials Current Trends and Government Interest
|
|
- Kimberly George
- 6 years ago
- Views:
Transcription
1 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Why you Should Care about Activities Related to Clinical Trials Current Trends and Government Interest Craig Metz, PhD Vice President, Regulatory, GlaxoSmithKline Ned Kelly, MD Vice President, Global Pharmacovigilance, Quintiles Mark DeWyngaert, PhD MBA Managing Director, Huron Consulting Group November 8, 2007
2 Critical Considerations for Clinical Research in Emerging Regions (ERs) Craig A. Metz, PhD Vice President, Regulatory GlaxoSmithKline
3 Key Points to Consider Data Integrity Generalizability Ethics
4 What s Being Said About Studies in ERs
5 Notable Quotes In addition to manufacturing challenges, Dr. Woodcock explained that FDA has to interpret and extrapolate data from clinical trials conducted overseas. We have to figure out how to deal with...intensified in recent years... extrapolating findings from one population, maybe a Third World-type of population, to our population and making sure the drug could still be safe and effective...under the conditions of the United States.
6 Notable Quotes John Jenkins, who spoke on an audiencesubmitted question with CDER associate director for medical policy Robert Temple, said the trend has also caused FDA to have concerns about the local standards of medical practice and how that may influence the ability to extrapolate and interpret the data that are brought back for consideration for the U.S. population.
7 Notable Quotes Robert Temple stated, I m more worried about depression studies. We ve had some fairly stunning examples of at least one drug that looked pretty good in studies in South America and Eastern Europe, and we re finding them not replicable in Western Europe and the U.S. We have no idea what that means. We have no reason to think anybody cheated. it s extremely common to accept data that s collected from a wide variety of places in the world. Usually there s fair consistency and it s not a particular problem. I have to say we ve not seen studies from India yet. We ve seen a couple of giant Chinese studies that could very well figure in favorable actions but not India yet, although we all know people who are moving there. When you talk to companies about what they encounter, they re well aware that there are differences in delving through protocols that are different by region...
8 Notable Quotes Senator Grassley According to an FDA official interviewed by HHS OIG, about 20% to 25% of the trials for products that FDA oversees occur outside the U.S., and this number is growing. Because FDA s regulations generally do not apply to trials conducted outside of the U.S., the agency s oversight of foreign trials is limited. What steps, if any, is FDA taking to ensure the quality and integrity of data from foreign clinical trials, and what is FDA doing to improve its monitoring of such trials?
9 Notable Quotes EMEA Reflection Paper Clinical trials are now increasingly being conducted in countries outside the EU and the relevance of the data for EU patients is not always clear. In addition, there are now also examples of results of trials conducted globally, for which interpretation of the data for the EU was difficult.
10 Data Integrity Each FDA Division may have a different philosophy regarding data from ERs Are appropriate sensitivity analyses being conducted to evaluate the potential for regional effects? How/when do you obtain regulatory authority concurrence with your analytical plan? When are the regulatory authorities apprised of your enrollment balance across regions?
11 Data Generalizability Concerns Potential for unknown/poorly understood regional differences in medical practices/standard of care Potential impact of culture/language on the effective deployment of PROs in ERs Placebo response rates may be higher at ER for certain disease settings which could decrease study power and lead to failed trials The more subjective the primary registration endpoint is the more regulatory risk is invoked with a development program involving significant recruitment from ERs
12 Ultimate Goal APPROVAL NOT
13 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Challenges in Outsourcing Clinical Trial Operations to the Developing World The CRO Perspective, with an Emphasis on Drug Safety Ned Kelly, MD VP Global Pharmacovigilance Quintiles
14 WHO Definition of Developing Country In the process of moving towards the economic and social model of the longer established industrialized countries. Developing country represents a concept that does not lend itself to a precise definition Often reflects a value judgment Refers to a large number of countries that are not homogenous With respect to Pharmacovigilance, implies Insufficient funds for public health Insufficient access to medical care Insufficient control of quality and distribution of medicines Illiteracy or language problems in relation to medical and Healthcare communication In clinical trials, sponsor must seek to avoid these circumstances, or implement strategies to minimize them. Lindquist M. The Need for Definitions in Pharmacovigilance. Drug Safety 2007; 30 (10):
15 Headlines Clinical trials in India: The wind is blowing (Outsourcing-Pharma.com 20 Sep 2007) Staff remain core challenge for CROs in India (Outsourcing-Pharma.com 25 Sep 2007) [In India] the pharmaceutical industry is growing at a rate of nearly 9 per cent annually (Outsourcing-Pharma.com 27 Sep 2007) Population of China = Billion (Chinability.com 2007-Sep-27) Population of India = Billion (Wikipedia, 01Sep2007 estimate)
16 Benefits of Outsourcing to Developing World Access to patients: Asia-Pacific India and China together have 33% of world s populations; each has significantly developed medical infrastructure and improving clinical trials infrastructure Thailand, Singapore, Malaysia, Philippines Latin America South Africa Eastern Europe Especially for certain patient populations e.g., oncology, HIV Cost savings: labor costs are lower in developing world Some investigators are often more diligent about ICH guidelines than are US and EU counterparts (e.g. Eastern Europe) Some investigators in India have very high patient retention rates
17 Risks of Outsourcing to Developing World Limited number of qualified investigators and study coordinators Limited number of qualified CRO personnel Competition among CROs result in high turnover rate Is CRO quality adequate? Regulatory environment approaching ICH standards, but not always at ICH standards Concerns about intellectual property
18 Example Country: India Larger sponsors typically audit CRO/sites more than once during study Larger sponsors typically co-monitor at some site qualification visits Regulatory change (abolishment of Phase Gap ) in 2005 brought brisk increase in global clinical trials Standard of care in urban population (approx 350 M) approaches that of West prevalence of illness is approx 10%, or approximately 35 M patients in urban population Most patients participating in Phase III global trials in India are educated, middle class in urban areas Biggest constraint is paucity of trained investigators and coordinators Increase in FDA inspections of investigative sites in 2007
19 India: Challenge of Training Investigators As in the West, physicians in India are extremely busy Unlike physicians in the West, they can t afford Western CME costs Main motivation to become investigators is revenue No standard training curriculum for investigators in India Clinical-trial-naïve Indian physicians see themselves as good at clinical practice, but don t understand the regulatory term Good Clinical Practice Important to initiate some type of training effort prior to Investigators Meeting methods tend to be informal Efforts underway to bring investigator training curriculum to India
20 Using CRO as Intermediary CRO must have established local presence and access to best investigators CRO must have well-trained, capable personnel CRO must have SOPs in alignment with ICH global SOPs preferable CRO must have locally active QA Dept. Benefits of CRO well-established in country of operations: Knowledge of local languages and culture (important for site interactions) Knowledge of qualified investigators with good coordinators Knowledge of local medical culture and standards of practice Knowledge of local regulatory environment
21 CRO Challenges in Pharmacovigilance Very few trained and experienced personnel (e.g., Drug Safety Associates expert in processing safety cases) Must be trained from within Intense competition among CROs for qualified personnel Operations must cover multiple countries, languages, cultures, and regulatory reporting requirements New threat to CROs BPOs ( Business Process Outsourcing or Business Process Optimization ) Effective competitors at winning functional service provider work Do not function as a local drug safety department, but as a commodity processor of safety cases from all markets BPO promise: to learn and implement your business processes, then improve upon them yet to be confirmed in PhV field Risk in lack of domain knowledge of drug safety, a high-risk area of operations
22 Sponsor Risk Mitigation Good feasibility are you in the right countries for the patient population you need? Compare feasibility analyses from more than one source Is CRO capable in the developing country you ve chosen? If global CRO, how much in-country presence and history? If local CRO, do you know them well enough to trust them? Does CRO have training for investigators and coordinators? Does CRO have good staff training programs, good mentoring programs, and high retention rate? Audit of selected CRO(s) For global study, one global CRO is best approach (some sponsors choose different CROs for different regions and/or functions)
23 Are the chosen sites good? Sponsor Risk Mitigation Review site selection process in audit of CRO Review CRO s audit plan Have your CRA accompany one or more randomly selected CRAs from CRO on randomly selected site qualification visits Audit study, including audit a few sites already audited by CRO, and a few not audited by CRO Stay in collaborative partnership with chosen CRO(s) Remain aware of and sensitive to cross-cultural issues For example, most of the world has more high context culture than does the US For example, many countries have more than one culture, based on multiple ethnicities and/or modern business vs. traditional cultural differences
24 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Monitoring Audit Practices to Assure Data Validity and Trial Integrity An Independent Perspective Mark DeWyngaert PhD, MBA Managing Director Huron Consulting Group
25 Third Party Vendor Assessments: Pharmaceutical companies have a growing need to examine their relationships with third party vendors as a result of increased international, federal and state regulations. There is also a continued focus on the bottom line and a rising number of contracted responsibilities. Third party vendors are used in a number of capacities. Companies routinely employ the services of Clinical Research Organizations (CROs), medical education vendors, healthcare technology firms, and data management. Areas of concern for many pharmaceutical companies center around vendor efficiency, quality, security, contract fulfillment, and compliance with the ICH and FDA s GXPs Across all vendor relationships, pharmaceutical companies should be interested in : The sufficiency of contracts and vendor policies currently in place Whether current operating controls adequately regulate vendor activities The extent to which potential vulnerabilities are identified by current monitoring Sufficiency in the degree of oversight by sponsor
26 Assessments/Audits - CROs Using other reviewers provides assurance that compliance and ethical requirements are met and that there is high degree of independence from both Sponsor and Vendor Prior to CRO selection (optimal) Assess qualifications of key personnel Assess SOPs: comparability with internal SOPs and change control processes Review systems and processes for contracted services management Audits/Assessments at other times Routine, on-going basis Prior to any interim and/or final analysis Third party vendor contract terms For cause.
27 Identify Business Gaps and Risks Identify the regulations, guidelines, standards that apply to the respective process both local and in major markets Identify existing process from a-z, ie: how are adverse events reported. Include all business functions that relate to the activity Once the current state process is outlined, identify controls that are missing in the process, ie: clearly defined roles, objective policies, systems which have controls validated throughout the process, IT/manual systems for collecting data, duplications etc. Policies, i.e.: investigator Training, payments to trial participants, data collection and validation, site selection, trial drug control Audit and monitoring plans Systems, ie: data integrity, function, checks and balances Define to be process and identify action steps to address the gaps in the as is process Monitoring plan should be designed with the Compliance Program goals in mind.
28 Practical Considerations Related to Auditing and Monitoring Strategy Developing your Auditing and Monitoring Plan Deciding what to monitor Prioritize Risk Areas Internal Factors, i.e. any system changes, people changes, etc. External Factors, i.e. new regulation, national and local enforcement etc. Compliance Program Identify controls that make the process work : Determine overall purpose to be effective Resources available to execute plan Consider integration with Internal Audit Plan Identify timeframes for audits and monitoring Communication and Commitment to Plan to Vendors and Internal
29 Third Party Vendor Assessments: Objective and Scope The assessment should evaluate the comprehensive performance of a third party vendors by closely examining their adherence to contractual obligations and the effectiveness of their processes and controls. On-site On-site audits* audits* of of vendors vendors Accuracy Accuracy of of billing billing and and invoices invoices Review Review of of contract contract terms terms against against work work performed performed Investigator Investigator eligibility eligibility and and payments payments Third Third Party Party Vendor Vendor Assessments Assessments Program Program management management Compliance Compliance with with regulatory regulatory guidelines guidelines Testing Testing of of selected selected documentation documentation Compliance Compliance with with your your company s company s policies, policies, procedures, procedures, and and practices practices Assessment = Process and procedural review, transaction testing, and data analysis on a scope basis to provide an assessment of compliance for internal purposes.
30 Questions Mark A DeWyngaert PhD MBA Managing Director Huron Consulting Group mdewyngaert@huronconsultinggroup.com
Ethics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationBribery and Research Integrity in Foreign Clinical Trials: Practical Strategies for Reducing Your Company s Compliance Risks
November 3, 2011 Bribery and Research Integrity in Foreign Clinical Trials: Practical Strategies for Reducing Your Company s Compliance Risks Sue Sefarian Health Care Compliance Officer Johnson & Johnson
More informationWHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific
WHITE PAPER establishing a regulatory Drug Development Strategy for Asia Pacific ppdi.com July 2012 EXECUTIVE SUMMARY As the economic power of China and other Asian countries grows, many biopharmaceutical
More informationHow to rescue a clinical trial
How to rescue a clinical trial Clinical trial conduct is demanding and rigorous, especially in orphan indications where patient populations are small. Even well-qualified, specifically selected Contract
More informationRegulatory system strengthening
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/32 Provisional agenda item 15.6 14 March 2014 Regulatory system strengthening Report by the Secretariat 1. The Executive Board at its 134th session noted an earlier
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationEstablishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationClinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationAn exploration of the Contract Research Organisation sector in. Divya Bhagianadh
An exploration of the Contract Research Organisation sector in India Divya Bhagianadh Global scenario Outsourcing clinical trials- the new trend Estimated CRO market revenues 2000-2010e ($ bn) Total market
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationApril 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
More informationVendor Selection: Identifying Effective Procedures & Strategies
Outsourcing Clinical Trials Canada 15 th November 2012 Vendor Selection: Identifying Effective Procedures & Strategies John S Andrews PhD President and CSO, NeurAxon Inc President, Ketogen Inc CSO, Talon
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationSupplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan
Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationClinical Trials in India Regulatory Issues
Clinical Trials in India Regulatory Issues Prem Pais MD Dean & Professor of Medicine St. John s Medical College Head, Clinical Trials Division St. John s Institute of Population Health and Clinical Research
More informationComplex Generics: Charting a new path
White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.
More informationRisk-Based Monitoring in Clinical Trials: A Cross-Functional Approach
Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach Sharon Herbert, PhD. - Senior Medical Research Manager Tyson Rogers, MS - Senior Principal Medical Research Biostatistician Clinical
More informationInt. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets
Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationDepartment At-A-Glance
Integrated Site Services Functional Role Integrated Site Services (ISS) includes global and country Start-Up and Regulatory units (RSU) and Integrated Patients & Site Services (IPSS). Our department s
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More informationData Reliability - Internet
Data Reliability - Internet Wikipedia https://en.wikipedia.org/wiki/reliability_of_wikipedia Others http://www.dailymail.co.uk/health/article- 2639910/Do-NOT-try-diagnose-Wikipedia-90-medicalentries-inaccurate-say-expertsDo.html
More informationPAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationCompliance Program Effectiveness Guide
Compliance Program Effectiveness Guide June 2017 This Guide is a comparison of: Compliance Program Elements New York State, Social Services Law 363-D Office of Inspector General (OIG) Compliance Program
More informationDATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS
GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017 DATA INTEGRITY & CSV:
More informationCTS East Coast. Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization. Connect with us to connect with Asia
Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization Connect with us to connect with Asia CTS East Coast Oct 19 th, 2011 Philadelphia Introduction Zuellig Pharma Asia Pacific
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationApplicability of US Regulations to Canadian Research
Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc.
ICH GCP E6(R2): Changes? Yes Challenges? Not as Difficult as You May Fear Lorrie D. Divers, President QRCP Solutions, Inc. 25 October 2017: University of Rochester Achieving High Quality Clinical Research
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationEuropean Medicines Agency Perspective
European Medicines Agency Perspective WMA Workshop on revision of DoH, 4-6 Dec 2012, Capetown, South Africa. Presented by: Fergus Sweeney, PhD Head of Sector, Compliance and Inspection, European Medicines
More informationThe University of Texas Southwestern Medical Center Institutional Review Board Oversight Audit. Internal Audit Report 14:07
Office of Internal Audit The University of Texas Southwestern Medical Center Institutional Review Board Oversight Audit Internal Audit Report 14:07 November 17, 2014 Table of Contents I. Executive Summary
More informationInvestigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents
Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations
More informationThe Science of Small Clinical Trials
The Science of Small Clinical Trials Introduction to Small Clinical Trials an Industry Perspective Simon Day, PhD Confucius (allegedly) When it is obvious that the goals cannot be reached, don t adjust
More informationCHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS
Clinical Trial Supply 28 th 29 th October 2014 Princeton, NJ - USA CHALLENGES OF GLOBAL CLINICAL TRIAL SUPPLY SOURCING SOME SPECIFICS FOR EMERGING MARKETS 1 Agenda The challenges associated with various
More informationExperience with Adaptive Dose-Ranging Studies in Early Clinical Development
Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Judith Quinlan MSc Vice President Adaptive Trials Cytel Inc. judith.quinlan@cytel.com Thanks to members of the PhRMA Adaptive
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationImportance of Pharmacovigilance for Pharmaceutical Industry
Importance of Pharmacovigilance for Pharmaceutical Industry JARIR AT THOBARI, MD, DPHARM, PHD FACULTY OF MEDICINE GADJAH MADA UNIVERSITY YOGYAKARTA, INDONESIA Role of Pharma Company Globally Investment
More informationSTATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY
STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY State of the Asia-Pacific Pharmaceutical Industry The pharmaceutical industry in the Asia-Pacific region has recently been besieged
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationCompliance Plans. Kelly S. McIntosh July 20, 2017
Compliance Plans Kelly S. McIntosh July 20, 2017 Roadmap The importance of compliance and compliance programs Common compliance issues know your risk areas! Guidance for drafting or updating your compliance
More informationAllergan plc COMPREHENSIVE COMPLIANCE PROGRAM
Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM 1. Compliance with Law All colleagues, officers and directors of the Company shall respect and comply with all applicable federal, state, local and foreign
More informationSOUTHWEST AIRLINES CO. AUDIT COMMITTEE CHARTER
SOUTHWEST AIRLINES CO. AUDIT COMMITTEE CHARTER The Audit Committee of the Board of Directors of Southwest Airlines Co. shall consist of at least three directors, each of whom shall meet the independence
More informationRegulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB
Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationPrimary Care mcta 2013: Guidance for use
GUIDANCE ON USE OF THE MODEL CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN PRIMARY CARE (PRIMARY CARE mcta, 2013 VERSION) Background to the development
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationMeasuring Compliance Program Effectiveness
Measuring Compliance Program Effectiveness Measuring Compliance Program Effectiveness: A Resource Guide HCCA Hawaii Regional Debbie Troklus, CHC-F, CCEP-F, CCEP-I, CHRC, CHPC Aegis Compliance and Ethics
More informationClinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally
Clinical Trial Outsourcing: A Case Study For Small Biotechnology Companies Operating Globally Cerus Corporation Concord, CA Laurence Corash, MD Chief Medical Officer Meisa Propst, Associate Director Clinical
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationShared Services in the Financial Services Industry: An Operating Model to Reach Strategic Goals
Shared Services in the Financial Services Industry: An Operating Model to Reach Strategic Goals Financial institutions have sought to enhance back- and middle office operations to deliver sustainable cost
More informationCRO Outlook 2015: A Paperless Path to a Competitive Advantage
CRO Outlook 2015: A Paperless Path to a Competitive Advantage Dec 22, 2014 By Jennifer Goldsmith Applied Clinical Trials All signs indicate that 2015 should be another good year for contract research organizations
More informationStephanie Gentilin, CCRA
Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring
More informationOutsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018
Outsourcing in Clinical Trials West Coast: Medical Device Stream Burlingame, CA February 22 nd 2018 Speakers Confirmed: Lian Cunningham, Vice President, Clinical Affairs and Regulatory Affairs, BAROnova
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationOptimising the Contribution of Regulatory Affairs to Product Development, Maintenance and Commercialisation
TOPRA MODULE Optimising the Contribution of Regulatory Affairs to Product Development, Maintenance and Commercialisation Case study 2 - Management of Regulatory Affairs Department ENABLING AND PROMOTING
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationMaking Life Easier for Investigators: A Shared Solution for Smarter, Faster Clinical Trials
Cognizant 20-20 Insights Making Life Easier for Investigators: A Shared Solution for Smarter, Faster Clinical Trials The industry s Shared Investigator Platform significantly reduces the time and cost
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationRoadmap for Managing Multiple CRO Vendors
PharmaSUG 2017 - Paper PO27 Roadmap for Managing Multiple CRO Vendors Veena Nataraj, Shire, Lexington, MA Karin LaPann, Shire, Lexington, MA ABSTRACT When working with CROs, the relationship established
More informationAICPA STANDARDS FOR PERFORMING AND REPORTING ON PEER REVIEWS. Effective for Peer Reviews Commencing on or After January 1, 2009
AICPA STANDARDS FOR PERFORMING AND REPORTING ON PEER REVIEWS Effective for Peer Reviews Commencing on or After January 1, 2009 Guidance for Performing and Reporting on Peer Reviews Copyright 2008 by American
More informationTrial oversight SOP for HEY-sponsored CTIMPs
R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system
More informationSponsor/CRO Partnership Optimization
Insight Brief Sponsor/CRO Partnership Optimization Developing a CRO Governance Model Geoff Garabedian, Vice President and Managing Director, Consulting at Quintiles Josh Samon, Principal Life Sciences
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationThe Future of Generic Pharmaceuticals
The Future of Generic Pharmaceuticals David R. Gaugh, R.Ph. Senior Vice President, Sciences and Regulatory Affairs Generic Pharmaceutical Association A Look Ahead Aging Demographics 1 YEARS OF AGE A Look
More informationUpdate on Current FDA Policies and Priorities
Update on Current FDA Policies and Priorities Vernessa Pollard MassMEDIC FDA Update December 12, 2017 Boston Brussels Chicago Dallas Düsseldorf Frankfurt Houston London Los Angeles Miami Milan Munich New
More informationKristin Peck. John Young. Pfizer: Think Digital First. An interview with. EVP WW Business Development and Innovation, Pfizer
An interview with Kristin Peck EVP WW Business Development and Innovation, Pfizer John Young President and General Manager Primary Care, Pfizer Pfizer: Think Digital First Transform to the power of digital
More informationHANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP)
HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION WHO Library Cataloguing-in-Publication Data
More informationReimagining Life Sciences With AI-Enabled Digital Transformation. Abstract
Reimagining Life Sciences With AI-Enabled Digital Transformation Abstract Technological, regulatory and environmental changes, along with an increasingly active involvement of patients in their treatment
More informationInvisible Ink in GLP and GCP Research
http://www.colginconsulting.com/invisible-ink-in-glp-and-gcp-research/ Invisible Ink in GLP and GCP Research What follows is more or less a transcript of my presentation at the annual meeting of the Pacific
More informationINTRODUCTION. Overview of Compliance Program. I. Leadership and Structure. GSK Ethics & Compliance Program US Operations
GSK Ethics & Compliance Program US Operations INTRODUCTION GlaxoSmithKline (GSK) is one of the world s leading research-based pharmaceutical and healthcare companies. GSK s global mission is to improve
More informationExecutive Compensation
Governance 50 Highlights Revised Corporate Governance Principles to provide that the Board will annually elect a Chairman of the Board, who may or may not be the CEO. Updated Lead Independent Director
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationOutsourcing and Localization. Marcos Mayo Director in Supply Management, A.T. Kearney
Outsourcing and Localization Marcos Mayo Director in Supply, A.T. Kearney 10 years of consulting experience in Supply (North America, Europe and the Middle East) Focus areas: - Large procurement transformation
More informationPharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai
Dayanidhi B, Amol S School of Pharmacy and Technology Management, NMiMS University, Mumbai The US$65-billion (in 2005), global R&D pie is expected to grow to US$l00-billion by 2010. If India secures even
More informationContents. Deloitte s Capabilities in the Public Health Sector. Leadership and Governance. Supply Chain Management. Organisational Development
Public Health Contents Deloitte s Capabilities in the Public Health Sector 1 Leadership and Governance 3 Supply Chain Management 3 Organisational Development 4 Health Finance 6 Data Management and IT
More informationPharmaceutical Congress Spring Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers
Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003 Agenda Introductions & Objectives Overview of Industry Practices
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationChapter 1. Pharmaceutical Industry Overview
Chapter 1 Pharmaceutical Industry Overview 1.1 Introduction 2 1.2 Regulations 2 1.2.1 Health Insurance Portability and Accountability Act 2 1.2.2 The Code of Federal Regulations 3 1.2.3 Guidance for Industry
More information